Understanding peptic ulcer disease pharmacotherapeutics.
The implication that Helicobacter pylori is responsible for peptic ulcer disease (PUD) has revolutionized the pharmacotherapeutic management of PUD. There has been a shift from long-term therapy with antacids and histamine2 (H2) antagonists to short-term therapy with triple antimicrobials with or without an antisecretory agent or a double antimicrobial therapy with an antisecretory agent. A case of PUD in a 53-year-old woman and its management with double antimicrobial agents and an antisecretory agent is discussed. Research evidence suggests that a treatment regimen aimed at eradicating H. pylori without diagnostic testing enhances the ability to effectively manage suspected cases of PUD before complications arise and referrals to specialists are necessary. Discouraging the use of over-the-counter H2 antagonists, ruling out long-term use of nonsteroidal anti-inflammatory drugs before selecting the treatment regimen, and considering expected treatment compliance are important aspects of PUD management that emerged from this case.
Navuluri
R
R
Lea Regional Medical Center Intensive Care Unit, Hobbs, N.M., USA.
Yue
S
S
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use*; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000382:microbiology*
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D008795:Metronidazole; D017291:Clarithromycin; D009853:Omeprazole